Fuso Pharmaceutical Industries,Ltd.

Tokyo Stock Exchange 4538.T

Fuso Pharmaceutical Industries,Ltd. Revenue for the year ending March 31, 2024: USD 366.07 M

Fuso Pharmaceutical Industries,Ltd. Revenue is USD 366.07 M for the year ending March 31, 2024, a -4.67% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Fuso Pharmaceutical Industries,Ltd. Revenue for the year ending March 31, 2023 was USD 383.99 M, a -5.82% change year over year.
Fuso Pharmaceutical Industries,Ltd. Revenue for the year ending March 31, 2022 was USD 407.73 M, a -8.33% change year over year.
Fuso Pharmaceutical Industries,Ltd. Revenue for the year ending March 31, 2021 was USD 444.75 M, a 1.98% change year over year.
Fuso Pharmaceutical Industries,Ltd. Revenue for the year ending March 31, 2020 was USD 436.13 M, a 4.96% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Tokyo Stock Exchange: 4538.T

Fuso Pharmaceutical Industries,Ltd.

CEO	Mr. Mikio Toda
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	1-7-10, Doshomachi
Employees	1,370
Sector	Consumers Staples
Industries Cleaning Supplies Automotive Parts Composite Materials Hardware & Electronics Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics

Description

Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate properties. The company was founded in 1937 and is headquartered in Osaka, Japan.

Key trends

Past 5 years